Use your leftovers: answers for excess stock

By Durbin

The size, complexity and geographical distribution of clinical trials can often lead to stock being left over, either at specific sites during the trial or overall following its conclusion. What to do with these pharmaceuticals can be something of a head-scratcher, but Durbin has the experience and know-how necessary to deal with this issue in as efficient and cost-effective manner as possible.

Enter your details below to view the free white paper

By downloading this White Paper, you acknowledge that may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Business Trade Media International Limited may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.